헬릭스미스

Helix Smith Engensis to resume Phase III clinical trial next year ...brHelix-Smith said he was convinced of the safety and efficacy of diabetic neuropathy (DPN) gene therapy genesis (development name, VM202-DPN).brbrHelix Smith, Kim Sun-young to sell 100,000 shares…br[Reporter E-Daily Kim Seong-Hoon] President Kim Sun-young Helix Smith (084990) sold 100,000 shares (0.47%) of the companys common stocks to the market at 7,6428 won per share.brbr3-phase failure Helix Smith VM202 is an unfinished success…brBiotechnology company Helixsmith, a gene therapy genesis (development name VM202-DPN) global phase 3-1 trial, is in vain.brbr[Breaking News] Sunyoung Kim, CEO of Helix Smith VM202 Safety and Effect ...brKim Sun-young, CEO of Helix Smith, is confident of the safety and effectiveness of GENSIS (VM202-DPN), a candidate drug for the treatment of diabetic neuropathy, which failed to ...brbrThe 2nd Shillazen Helix SmithbrHelix Smith, who failed to draw the conclusions of the new drug clinical trial, met the lower limit for two consecutive days.brbrHelix Smith shares fell -10.6% at present ...brIn addition to Helix Smith, NanoCamtech (-10.02%), Namsun Almiu (-10.51%), TK Chemical (-10.11%), Ocean Metals (-10.36%) and Namsun Aluminum (-10.74%)brbrTwo relatives of Helix Smith, 500 million won before the clinical failure disclosure ...brTwo related parties of CEO Sun-Young Kim, the largest shareholder of Helix Smith, reported that the company sold about 500 million won worth of shares in the market on the 23rd when the company announced the clinical drug failure after closing.brbrOn the 26th, Helix Smith (-9.52%) and Megion (+16.1 ...brOn the 26th, KOSDAQ net purchases such as Helix Smith (-9.52%) and Megion (+ 16.1%) ... Foreign investors focus on Helix Smith, Megion, KM ...brbr[Feature] Helix Smith, give me 80,000 won…brHelix Smith declined for eight consecutive trading days, finally paying 80,000 won.brbrKim Sun-young, CEO of Helix Smith Announces Results of DPN3-1 Awardbr[Photo] Kim Sun-young, CEO of Helix Smith to announce results of DPN3-1 Award ...brbr